Fralin Life Science Institute

Applications are now being accepted to support rising VT sophomores, juniors and seniors to pursue life sciences research full-time (40 hours/wk) during the summer of 2010.

Applicants must identify a faculty sponsor with whom they intend to work, and the student and sponsor should prepare this application together. Eleven fellowships of $4000 each will be awarded(subject to taxes and withholdings), paid over a 10-week period. The 10-week period begins on 6/1/10 and ends on 8/10/10.

The application may be downloaded below:

Exceptional incoming students working with Fralin Institute affiliated
faculty are eligible for a Fralin Graduate Fellowship. These

By Susan Trulove

Kevin P. Davy, professor in human nutrition, foods and exercise, has been invited to serve as a member of the Clinical and Integrative Diabetes and Obesity Study Section of the NIH Center for Scientific Review (CSR) until June 30 2013. Members are selected on the basis of their demonstrated competence and achievement in their scientific discipline as evidenced by the quality of research accomplishments, publications in scientific journals, and other significant scientific activities, achievements and honors.

(July 1, 2009) Prof. Timothy Long has been named Associate Director for Interdisciplinary Research and Education at Virginia Tech's Fralin Life Science Institute.

A five-year-old Virginia Tech outreach program, which has more than 12,000 high school students doing research and providing results that scientists can use, has received a $1.3 million Science Education Partnership Award from the National Center for Research Resources (NCRR), a component of the National Institutes of Health.

Novozymes Biologicals, Inc., an international corporation, and the Fralin Life Science Institute at Virginia Tech are pleased to announce summer internship opportunities designed to provide undergraduate students with an opportunity to develop real world experience at the interface of life science and business.

By Catherine Doss
BLACKSBURG, Va., January 25, 2010 -- Compounds developed by researchers at Virginia Tech, have proven effective in destroying breast cancer cells when used with lasers developed by Theralase Technologies (TSX-V: TLT) out of Toronto. Theralase, an international manufacturer of laser medical devices, reports that its patented photodynamic compounds (PDCs) developed at the university, when used with its lasers, destroy breast cancer cells in pre-clinical trials.